CONFERENCE - Biotechnology Innovation Organization

CE NVESTOR

CE CONFERENCE

February 12-13, 2018 ? New York Marriott Marquis

NVESTOR

CONFERENCE

February 12-13, 2018 New York Marriott Marquis

Audience Demographics

Now in its 20th year, the BIO CEO & Investor Conference is one of the largest investor conference focused on established and emerging publicly traded and select private biotech companies.

C-LEVEL 62%

DIRECTOR 15%

VP

OTHER

14%

9%

Breakdown by Market Cap

42%

< 50M

25%

$100M-250M

16%

$50M-100M

13%

> $500M

4% $250M-500M

Company Types

Biotech or pharma, therapeutic R&D 58%

All Others 1% Institute, Hospital Research 1% Digital Health 1% Patient Advocacy 1%

IT, Information 1% Other R&D Services 2% Investment Bank 2% Academic, Tech Transfer 2% CMO, CRO 2% Biotech or Pharma, Animal Health 2% Synthesis, Analytic, Diagnostic Services 3% Financial, Legal, Consulting 5%

Public, NPO, Govt., Economic Development 6%

Medical Device or Technology 6%

Other Products or Services 7%

Attendees: 1,400+ Countries Represented: 28 BIO One-on-One

Meetings: 2,600+ Registered Investors: 650 Company Presentations: 190 Expert Speakers: 58

Therapeutic Focus

Oncology 31%

Other 26%

Cardiovascular 4% Metabolic Diseases 4% Gastrointestinal 4% Infectious Diseases 5% Gene/Cell Therapy 5%

Orphan/Rare Diseases 6%

Diagnostics 7%

CNS/Neurological 9%

Event & Sponsorship Prospectus

CEO ? #BIOCEO18

CE NVESTOR

CONFERENCE

Past Fireside Chat Speakers

February 12-13, 2018 ? New York Marriott Marquis

Giovanni Caforio, MD

Chief Executive Officer Bristol-Myers Squibb

Tony Coles, MD

Chairman and Chief Executive Officer Yumanity Therapeutics

J. Joseph Kim, PhD

President and Chief Executive Officer Inovio Pharmaceuticals

Jeffrey D. Marrazzo

Co-Founder and Chief Executive Officer Spark Therapeutics

Lynn Seely, MD

Chief Executive Officer Myovant Sciences

Event Attributes and Opportunities

EXPERIENCE the largest, unbiased forum where institutional investors, industry analysts, and senior biotechnology executives shape the future investment landscape of the industry.

HEAR Washington's perspective on policy and other timely developments affecting the industry.

EVALUATE fresh investment opportunities including compatible, complementary, and competitive companies.

LEARN about the hottest clinical developments and industry catalysts by attending the conference's therapeutic workshops and business roundtables.

ATTEND fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry's leading companies are headed in 2018.

GAIN ACCESS to BIO One-on-One PartneringTM for scouting potential investments and deal partners, optimizing your time at the event.

UNIQUE PLATFORM for your company to highlight accomplishments and discuss upcoming milestones. Approximately 190 companies will be chosen based on a selection process evaluating a company's pipeline and R&D activities.

GET THE PULSE of the current and proposed investment trends in biotechnology.

NETWORK with peers, investors, and potential partners attending the conference and our exclusive receptions.

2017 Advisory Committee

John Chambers, President and Head of Investment Banking, H.C. Wainwright & Co., LLC

Barbara J. Dalton, PhD, Vice President, Venture Capital, Pfizer Inc.

Linda S. Grais, MD, President and Chief Executive Officer, Ocera Therapeutics, Inc.

Brian Hagerty, Senior Director, Head of Healthcare Capital Markets, New York Stock Exchange

Nouhad Husseini, Vice President, Business Development, Regeneron Pharmaceuticals, Inc.

Michael King, Managing Director and Senior Research Analyst, JMP Securities LLC

Jonathan Leff, Partner, Deerfield Management; Chairman, Deerfield Institute

Michael Margolis, RPh, Managing Director and Head of Healthcare Investment Banking, ROTH Capital Partners, LLC

Michael Mirsky, Managing Director, Investment Banking, H.C. Wainwright & Co., LLC

Timothy P. O'Connor, PhD, Executive Vice President, The Rockefeller University

Jason Park, Principal, Flagship Pioneering

Susan Peschin, MHS, President and CEO, Alliance for Aging Research

Dennis J. Purcell, Founder and Senior Advisor, Aisling Capital

Carlo Rizzuto, PhD, Partner, Versant Ventures

Matthew Roden, PhD, Vice President and Head of Strategic Corporate Development, Bristol-Myers Squibb

Stephen Sands, Vice Chairman Investment Banking and Chairman Global Healthcare Group, Lazard

Rajeev Shah, Managing Director & Portfolio Manager, RA Capital Management

Nathan Tinker, PhD, Executive Director, NewYorkBIO

Event & Sponsorship Prospectus

CEO ? #BIOCEO18

CE NVESTOR

CONFERENCE

2017 Sponsors

Supporting Bank Sponsors

Double Helix Sponsors

Conference Sponsors

February 12-13, 2018 ? New York Marriott Marquis

Helix Sponsor

Local Co-Host

Regional Sponsors

Event & Sponsorship Prospectus

CEO ? #BIOCEO18

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download